Testosterone 1000 mg Injection Solution Discount Agreement
Original notice title
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Testosteron (ATC-Code nach WHO: G03BA03)
Opportunity Score
Why this score?
Opportunity
60 / 100
Complexity
25 / 100
Risk factors
Purchase volumes are unknown and depend on prescribing and dispensing behavior. No minimum quantities guaranteed.
Buyer can terminate the open-house model early if exclusive agreements are concluded, typically 8-12 months after tende...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Tender facts
- Contracting authority
- AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen
- Country
- Germany
- CPV
- 33600000 - Pharmaceutical products
- Deadline
- Jul 31, 2027
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Jul 2027
- Provide Testosterone 1000 mg injection solution under a non-exclusive discount agreement with AOK PLUS.
- No exclusivity; multiple suppliers may participate.
Show full summary
This is a non-exclusive drug discount agreement (Rabattvereinbarung) under German SGB V for Testosterone (ATC G03BA03, 1000 mg injection solution) using an open-house model. Any qualified pharmaceutical entrepreneur can join by signing the agreement without negotiations. No guaranteed purchase volumes, no exclusivity. Agreement ends 31.07.2027. First submission deadline for 01.08.2025 start is 23.06.2025. Electronic submission via DTVP portal. No estimated value or award criteria specified.
Risks
Purchase volumes are unknown and depend on prescribing and dispensing behavior. No minimum quantities guaranteed.
Buyer can terminate the open-house model early if exclusive agreements are concluded, typically 8-12 months after tende...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical entrepreneur as per §4 Abs.18 AMG for the offered product.
- Maintain absolute confidentiality of the discount agreement content and discount amount.
Administrative
- Submit signed discount agreement and required declarations via DTVP portal.
Requirements may be incomplete.
Buyer
Location
Dresden, DEU
Website
Buyer profile
Identifier
DE256878834
Activity
Health
Lots (1)
LOT-0001
Testosterone 1000 mg Injection Solution Discount Agreement
Non-exclusive discount agreement for Testosterone 1000 mg injection solution under open-house model. Open to all qualified pharmaceutical entrepreneurs. No guaranteed minimum quantities.
Location
Duration
Category
Deadline
Award details
Siehe Kurzbeschreibung
Value note
Show original TED data
Original lot title
Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Testosteron (ATC-Code nach WHO: G03BA03)
Original TED description
Siehe Kurzbeschreibung
Procurement Details
- Publication date
- 29 May 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 349760-2025
Documents (1)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
60 / 100
Complexity
25 / 100
Risk factors
Purchase volumes are unknown and depend on prescribing and dispensing behavior. No minimum quantities guaranteed.
Buyer can terminate the open-house model early if exclusive agreements are concluded, typically 8-12 months after tende...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications